Date: 2013-03-11
Type of information: Grant
Company: Reneuron (UK)
Investors: Biomedical Catalyst Fund (UK)
Amount: £1.2 million
Funding type: grant
Planned used: The Biomedical Catalyst grants have been awarded to fund clinical development of ReN009 stem cell therapy candidate for critical limb ischaemia and pre-clinical development of ReN003 stem cell candidate for the treatment of retinitis pigmentosa.
Others: ReNeuron has been awarded two separate grants, totalling £1.2 million, from the UK Biomedical Catalyst to pursue further development of two of its core stem cell therapy candidates.
The first award to ReNeuron of £0.4 million is a Late Stage Biomedical Catalyst grant and relates to the Company’s ReN009 stem cell therapy candidate for critical limb ischaemia. The award will be deployed towards the funding of a UK Phase I clinical trial in limb ischemia patients. The Company will provide a further update on progress with this programme shortly.
The second award of £0.8 million is an Early Stage Biomedical Catalyst grant and relates to the Company’s ReN003 stem cell candidate for the treatment of retinitis pigmentosa. The award will fund the UK-based late pre-clinical development of this programme through to the clinic. This work is being undertaken in collaboration with the world-renowned UCL Institute of Ophthalmology and complements the Company’s existing long-standing collaboration on this programme with the US-based Schepens Eye Research Institute.
Therapeutic area: Rare diseases - Ophtalmological diseases
